Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.

Mumbai: Cipla has announced that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro ...

In 1996, Cipla introduced the first transparent dry powder inhaler. At the end of the 20th century, Cipla began a strategic partnership with multinational pharmaceutical company Ranbaxy Laboratories.

Motilal Oswal retains Neutral on Cipla; see limited upside due to delayed niche product approvals. Learn more about the ...

Asit C Mehta recommended accumulate rating on Cipla with a target price of Rs 1808 in its research report dated January 17 ...

“The margin improves every time we sell more respiratory products, which was the case in quarter three…this margin percentage is not a sustainable margin percentage for Cipla. Quarter four ...

CMSA, is a wholly owned subsidiary of Cipla, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical ...

Prabhudas Lilladher is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated January 29, 2025.